New hope against a deadly parasitic disease: LXE408 shows promise in phase II trial
NCT ID NCT05593666
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called LXE408 in 101 adults and teens with visceral leishmaniasis, a serious parasitic disease. Participants received one of two LXE408 doses or a standard treatment. The goal was to see if LXE408 could clear the parasite and improve symptoms by day 28. The trial is complete, and results will show how safe and effective the new drug is compared to the current standard.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
DrugsNeglectedD Investigational Site
Bīhar, India
-
DrugsNeglectedD Investigational Site
Patna, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.